Induction of long-lasting immunity against viral respiratory tract infections remains an elusive goal. Using a nonhuman primate model of human respiratory syncytial virus (hRSV) infection, we compared mucosal and systemic immune responses induced by different DNA delivery approaches to a novel parenteral DNA prime-tonsillar adenoviral vector booster immunization regimen. Intramuscular (i.m.) electroporation (EP) of a DNA vaccine encoding the fusion protein of hRSV induced stronger systemic immune responses than intradermal EP, tattoo immunization, and conventional i.m. DNA injection. A single EP i.m., followed by two atraumatic tonsillar immunizations with the adenoviral vector, elicited strong systemic immune responses, an unique persistent CD4+ and CD8+ T cell response in the lower respiratory tract and protection from intranasal hRSV challenge. Thus, parenteral DNA priming followed by booster immunization targeted to a mucosal inductive site constitutes an effective vaccine regimen for eliciting protective immune responses at mucosal effector sites.

Additional Metadata
Persistent URL dx.doi.org/10.1128/JVI.02736-13, hdl.handle.net/1765/59054
Journal Journal of Virology
Citation
Grunwald, T, Tenbusch, M, Schulte, R, Raue, K, Wolf, H, Hannaman, D, … Stahl-Hennig, C. (2014). Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates. Journal of Virology, 88(8), 3997–4007. doi:10.1128/JVI.02736-13